Clinical trials: sponsored by Akeso
Advanced Malignant Solid Tumor
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
- Trial name
- NCT06166472
- Testing
- AK132
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Akeso
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the…
- Trial name
- NCT05960955
- Testing
- Cadonilimab, AK117, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Locally Advanced or Metastatic NSCLC
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic…
- Trial name
- NCT05990127
- Testing
- AK104, Tislelizumab, carboplatin
- Where
- 62 sites in China
- Volunteers
- 642 people
- Sponsor
- Akeso
Heterozygous Familial Hypercholesterolemia
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia (HeFH).The primary objective of this study is to…
- Trial name
- NCT04173793
- Testing
- AK102, Statins and/or Ezetimibe
- Where
- 2 sites in China
- Volunteers
- 109 people
- Sponsor
- Akeso
Homozygous Familial Hypercholesterolemia
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double…
- Trial name
- NCT03933293
- Testing
- AK102, Statins, Ezetimibe
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Akeso
Hypercholesterolemia
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
- Trial name
- NCT04358432
- Testing
- AK102, Statins and/or Ezetimibe
- Where
- 2 sites in China
- Volunteers
- 262 people
- Sponsor
- Akeso
Hypercholesterolemia
A Long-term Study of AK102 in Patients With Hypercholesterolemia
This is a phase II, open-label, non-controlled, extended study. The main objective of this study is to evaluate the long-term efficacy and safety of AK102 in combination with basic lipid-lowering therapy in patients with…
- Trial name
- NCT04173403
- Testing
- 450mg AK102, 300mg AK102, 150mg AK102
- Where
- China
- Volunteers
- 796 people
- Sponsor
- Akeso
Psoriasis Vulgaris
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05120297
- Testing
- AK101
- Where
- 52 sites in China
- Volunteers
- 452 people
- Sponsor
- Akeso
Solid Tumor
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a single agent in adult subjects with…
- Trial name
- NCT04547205
- Testing
- AK109
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Peripheral T-cell Lymphoma
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of AK104，an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04444141
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
MSI-H/dMMR Solid Tumor
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable…
- Trial name
- NCT04547101
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Asthma
A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
- Trial name
- NCT05155020
- Testing
- AK120
- Where
- 19 sites in China
- Volunteers
- 1 people
- Sponsor
- Akeso
Advanced Solid Tumors
A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors
This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.
- Trial name
- NCT05393063
- Testing
- AK127
- Volunteers
- 36 people
- Sponsor
- Akeso
Hodgkin Disease Lymphoma
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT05244642
- Testing
- Penpulimab, Investigator's choice of Chemotherapy
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
Advanced or Metastatic Solid Tumors, Malignancy
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.
- Conditions
- Advanced or Metastatic Solid Tumors, Malignancy, Metastasis
- Trial name
- NCT05200273
- Testing
- AK114
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Akeso